



Peer-Review Statements

Arifah Sri Wahyuni^(✉), Lilla Prapdhani Agni Hajma, and Refsya Azanti Putri

Faculty of Pharmacy, Universitas Muhammadiyah Surakarta, Jl. A. Yani, Tromol Pos I,
Pabelan Kartasura, Sukoharjo 57162, Indonesia
arifah.wahyuni@ums.ac.id

All of the articles in this proceedings volume have been presented at the 4th ICCBP 2022 (International Conference of Current Breakthrough in Pharmacy 2022) during 14–15 January 2022 in Surakarta Indonesia. These articles have been peer reviewed by the members of the Scientific Committee and approved by the Editor-in-Chief, who affirms that this document is a truthful description of the conference’s review process.

1 Review Procedure

The reviews were *open*. Each submission was examined by 2 reviewers independently.

The conference submission management system was REMIT on <https://icb-pharma.ums.ac.id/2021/>

The submissions were first screened for generic quality and suitability. Authors choose directly the track that suitable with their articles. The track director then did the initial screening, and sent the article for peer review by matching each article’s topic with the reviewers’ expertise, taking into account any competing interests. An article could only be considered for acceptance if it had received favourable recommendations from the two reviewers.

Authors of a rejected submission were given the opportunity to revise and resubmit after addressing the reviewers’ comments. The acceptance or rejection of a revised manuscript was final.

2 Quality Criteria

Reviewers were instructed to assess the quality of submissions solely based on the academic merit of their content along the following dimensions:

1. Originality and level of innovativeness;
2. Thematic relevance for the call for papers;
3. Significance for theory or practice;
4. Methodology well discussed (Experimental planning and preparation);
5. Quality of Presentation of tables and figures.
6. Conclusion supported by results of work and future work.

In addition, all of the articles have been checked for textual overlap in an effort to detect possible signs of plagiarism by the publisher. Turnitin was used to detect the plagiarism.

A. Sri Wahyuni—Editor-in-Chief of the 4th ICCBP 2022.

© The Author(s) 2023

A. Sri Wahyuni et al. (Eds.): ICB-Pharma 2022, AHCPs 3, pp. 1–2, 2023.
https://doi.org/10.2991/978-94-6463-050-3_1

3 Key Metrics

Total submissions	74
Number of articles sent for peer review	74
Number of accepted articles	33
Acceptance rate	44.5%
Number of reviewers	17

4 Competing Interests

Neither the Editor-in-Chief nor any member of the Scientific Committee declares any competing interest.

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

